Table 1. Participant Baseline Characteristics in a Trial of Letermovir for Cytomegalovirus (CMV) Prophylaxis After Kidney Transplant in the Safety Population.
| Characteristic | No. (%) of participantsa | |
|---|---|---|
| Letermovir (n = 292) | Valganciclovir (n = 297) | |
| Age, y | ||
| Median (range) | 52.0 (18-82) | 51.0 (18-78) |
| 18-35 | 62 (21.2) | 62 (20.9) |
| 36-50 | 78 (26.7) | 84 (28.3) |
| 51-64 | 104 (35.6) | 96 (32.3) |
| 65-74 | 42 (14.4) | 47 (15.8) |
| ≥75 | 6 (2.1) | 8 (2.7) |
| Sex | ||
| Men | 213 (72.9) | 209 (70.4) |
| Women | 79 (27.1) | 88 (29.6) |
| Race | ||
| American Indian or Alaska Native | 3 (1.0) | 4 (1.3) |
| Asian | 4 (1.4) | 10 (3.4) |
| Black or African American | 21 (7.2) | 33 (11.1) |
| Missing | 2 (0.7) | 1 (0.3) |
| Multiple | 9 (3.1) | 6 (2.0) |
| White | 253 (86.6) | 243 (81.8) |
| Hispanic or Latino | 54 (18.5) | 44 (14.8) |
| Reason for transplant | ||
| Congenital cystic kidney disease | 52 (17.8) | 50 (16.8) |
| Hypertension | 42 (14.4) | 53 (17.8) |
| Diabetes/diabetic nephropathy | 39 (13.4) | 46 (15.5) |
| Glomerulonephritis | 37 (12.7) | 30 (10.1) |
| IgA nephropathy | 36 (12.3) | 26 (8.8) |
| Chronic kidney disease/end-stage kidney disease | 19 (6.5) | 20 (6.7) |
| Urinary obstruction | 8 (2.7) | 4 (1.3) |
| Tubulointerstitial nephritis | 3 (1.0) | 7 (2.4) |
| Alport syndrome | 4 (1.4) | 6 (2.0) |
| Renal atrophy | 5 (1.7) | 3 (1.0) |
| Lupus | 2 (0.7) | 5 (1.7) |
| Mesangioproliferative glomerulonephritis | 2 (0.7) | 1 (0.3) |
| Otherb | 43 (14.7) | 46 (15.5) |
| Use of lymphocyte-depleting induction immunosuppressionc | 134 (45.9) | 138 (46.5) |
| Donor type | ||
| Deceased | 171 (58.6) | 182 (61.3) |
| Living, not related | 65 (22.3) | 51 (17.2) |
| Living, related | 56 (19.2) | 64 (21.5) |
a
All randomized participants who received prophylaxis.
b
Other consisted of multiple single disease states with ≤4 participants in either group.
c
Use of ≥1 of the following at the time of transplant: horse-derived or rabbit-derived antithymocyte globulin, alemtuzumab, or muromonab CD3. Receipt of these agents is associated with an increased risk for CMV infection.